Daily Bio News Summary — 2026-08-12: AI biotechs, 340B lawsuits, and Definium's psychedelic breakthrough

Today’s Harvest: 33 articles across 8 sources

Today’s batch of 33 biopharma news articles spans therapeutics development (17), clinical regulatory (2), and business strategy (1), sourced primarily from BioSpace (8), Endpoints News (4), Fierce Pharma (3), Fierce Biotech (2), PR Newswire FDA (2), and STAT News (1).

The Headline: Definium’s Psychedelic Breakthrough

The top story today is Definium Therapeutics’ Phase 3 LSD anxiety readout. The company’s LSD-based therapeutic beat analyst expectations in the first of two Phase 3 anxiety disorder trials, marking a significant milestone for psychedelic medicine. (Endpoints News, 2026-08-12)

The Alnylam/BridgeBio ATTR Battle

A fascinating competitive dynamic emerged in the ATTR (transthyretin amyloidosis) space. Alnylam’s Amvuttra is falling short of expectations, with the company cutting sales guidance as demand shifts. Meanwhile, BridgeBio continues its ATTR ascent, with its drug Attruby gaining momentum. The stock market reacted sharply—Alnylam shares are down 30% despite a booming biotech market. (Endpoints News, 2026-08-12)

Lilly’s Retatrutide Copycat Crackdown

Eli Lilly is filing lawsuits versus 6 sellers of retatrutide copycats, cracking down on the black market for its obesity asset. This legal action signals Lilly’s determination to protect its GLP-1 franchise ahead of FDA approval. (Fierce Pharma, 2026-08-12)

AI Biotechs Force Biopharma into ‘Fail-Fast’ Mode

With tech backing, AI biotechs are pushing biopharma into a ‘fail-fast’ drug development paradigm. This shift reflects the growing influence of AI-native companies in drug discovery and development. (BioSpace, 2026-08-12)

340B Lawsuits Escalate

AbbVie, Novartis, and Bristol Myers have all filed 340B lawsuits in Illinois, continuing the ongoing battle over drug pricing and discounts in the 340B program. (Endpoints News, 2026-08-12)

Sentynl/Mereo Rare Disease Deal

Sentynl is betting up to $475M in a licensing deal for Mereo’s rare lung disease asset, highlighting continued interest in rare disease therapeutics. (BioSpace, 2026-08-12)

AI Reality Check from Insurers

Two health insurers gave an AI reality check, suggesting that while AI in healthcare is gaining traction, insurers are taking a measured approach to adoption. (Endpoints News, 2026-08-12)

Exelixis Patent Strategy Questioned

Researchers are questioning whether Exelixis used a ‘trivial’ modification to its cash cow to product-hop past a patent cliff, raising important questions about pharmaceutical patent strategies. (Endpoints News, 2026-08-12)

FDA Rejects ITM’s Radiopharma Therapy

The FDA rejected ITM Isotope’s radiopharma therapy over manufacturing issues, a reminder that manufacturing quality remains a critical barrier in drug development. (BioSpace, 2026-08-12)

Fresenius Kabi’s Actemra Biosimilar Recall

Fresenius Kabi launched a US recall of its Actemra biosimilar, highlighting the challenges biosimilar manufacturers face in maintaining quality standards. (Fierce Pharma, 2026-08-12)

What This Batch Is NOT Telling Us

Today’s harvest is notably absent of:

• Major IPO announcements (though the pipeline remains active)
• Large-scale M&A deals (the Sentynl/Mereo deal is the largest at $475M)
• FDA approvals (no new drug approvals today)
• Clinical trial failures (most readouts are positive or neutral)

Reading Order for Limited-Time Readers

1. Definium’s Phase 3 LSD anxiety readout — the day’s most significant clinical milestone
2. Alnylam’s Amvuttra guidance cut — important competitive dynamics in ATTR
3. Lilly’s retatrutide lawsuits — GLP-1 market protection strategies
4. AI biotechs’ ‘fail-fast’ impact — industry transformation narrative
5. AbbVie/Novartis/BMS 340B lawsuits — drug pricing policy developments

How to Read the Underlying Articles

All source articles are available in the src/content/news/ folder. Each file contains sourceUrl and sourceName fields pointing to the original article.

---

Article Index

1. Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout (Endpoints News, 2026-08-12)
2. BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations (Endpoints News, 2026-08-12)
3. Lilly files lawsuits versus 6 sellers of retatrutide copycats (Fierce Pharma, 2026-08-12)
4. With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development (BioSpace, 2026-08-12)
5. AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinois (Endpoints News, 2026-08-12)
6. Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset (BioSpace, 2026-08-12)
7. Two health insurers give an AI reality check (Endpoints News, 2026-08-12)
8. Did Exelixis use a ‘trivial’ modification to its cash cow to product-hop past a patent cliff? (Endpoints News, 2026-08-12)
9. FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues (BioSpace, 2026-08-12)
10. Fresenius Kabi launches US recall of Actemra biosimilar (Fierce Pharma, 2026-08-12)
11. Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drug (Endpoints News, 2026-08-12)
12. After trimming headcount, Aardvark drops trials as wait drags on (Fierce Biotech, 2026-08-12)
13. CytoDyn’s leronlimab reaffirms HIV potential with macaque study (Fierce Biotech, 2026-08-12)
14. Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight (BioSpace, 2026-08-12)
15. Snapchat creates ad format to support pharma disclosure needs (Fierce Pharma, 2026-08-12)
16. The Lindsay Clancy case shows the limits of postpartum psychiatry (STAT News, 2026-08-12)
17. Why a missed promotion isn’t always about you (BioSpace, 2026-08-12)
18. 7 companies hiring in North Carolina now (BioSpace, 2026-08-12)
19. Abbott taps telenovela star to take the drama out of cancer test (Fierce Pharma, 2026-08-10)
20. Epicrispr secures $90M after early data on epigenetic FSHD treatment (BioSpace, 2026-08-10)
21. Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment (Endpoints News, 2026-08-10)
22. Amgen lays groundwork for new R&D center in Hyderabad (Fierce Biotech, 2026-08-11)
23. Datasea Announces FDA Registration and Device Listing for NeuroVibe (PR Newswire FDA, 2026-08-11)
24. Focus Health’s Irving Health & Wellness Clinic Expands Medical Weight Loss Program (PR Newswire FDA, 2026-08-11)
25. Galvanize Therapeutics Announces First Commercial Procedures (PR Newswire FDA, 2026-08-11)
26. Stopping statins in people over 75 at low risk for heart disease (STAT News, 2026-08-11)
27. WuXi AppTec wins temporary relief in DOD classification feud (Fierce Pharma, 2026-08-11)
28. Neuralytix Announces Full Commercial Availability of iD3 System (PR Newswire FDA, 2026-08-12)
29. New Peer-Reviewed Study Shows 98% Technical Success for Mendaera (PR Newswire FDA, 2026-08-12)
30. Vectra AI Achieves FedRAMP High Authorization (PR Newswire FDA, 2026-08-06)
31. Menu-Order AI Names Dr. Leigh-Anne Dale as Founding Medical Advisor (PR Newswire FDA, 2026-08-05)
32. In the Lab (BioSpace, 2026-08-05)
33. Infinimmune Secures $75M for Better Antibody Drugs (BioSpace, 2026-08-01)